arrow
K

Kelly Chun

labcorp
H指数:13
被引数:659

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapeutic Drug Monitoring (TDM) Assays to Quantify Risankizumab Drug and Anti-Risankizumab Antibodies in Individuals Treated with IL23 Inhibitor Risankizumab for Chronic Autoimmune Diseases

治疗药物监测(TDM)检测试剂盒,用于测定接受IL23抑制剂Risankizumab治疗的慢性自身免疫性疾病患者体内的Risankizumab药物和抗Risankizumab抗体水平

2025-10-010
OAAI
Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease

Moses, J.; Adler, J.; Saeed, S.A.; Firestine, A.M.; Galanko, J.A.; Ammoury, R.F.; Bass, D.M.; Bass, J.A.; Bastidas, M.; Benkov, K.J.; 等. 维持期低抗肿瘤坏死因子水平与克罗恩病患儿的疗效失败相关。Inflamm. Bowel Dis. 2025, 31, 1841–1850. [Google Scholar] [CrossRef] [PubMed]

2024-10-012
PRE
Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease
2024-10-010
OA
Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease
2024-07-014
PRE
Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report

SARS-CoV-2再感染及体液免疫减弱1例报告

2022-12-204
OAAI
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance
2022-10-3113
OA
Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease
2022-09-1610
OA
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection
2022-08-317
OAAI